Background. Evidence is limited to guide the management of children exposed to multidrug-resistant (MDR) tuberculosis. We aimed to study the tolerability and toxicity of a standard preventive therapy regimen given to children exposed to infectious MDR tuberculosis, and explore risk factors for poor outcome.
has implications for the community as children provide a reservoir for future disease, with propagation of the epidemic by those children who develop infectious tuberculosis. The first trials of isoniazid as preventive therapy for tuberculosis were carried out >50 years ago [4] , and isoniazid has been demonstrated to reduce the risk of progression from infection to disease in HIV-positive and HIV-negative children following exposure to drug-susceptible tuberculosis [5, 6] . The majority of international agencies and national tuberculosis programs therefore advise providing children <5 years and all HIVpositive children with isoniazid daily for 6 months following exposure to an infectious case of drug-susceptible tuberculosis [7] .
Multidrug-resistant (MDR) tuberculosis is caused by M. tuberculosis resistant to at least rifampin and isoniazid [8] . Following exposure to a source patient with MDR tuberculosis, it is unclear how children should be managed [9] . Although concordance between putative source cases and child contacts is not complete, many clinicians are uncomfortable treating a child exposed to an MDR organism with isoniazid. Cases have been reported of children exposed to MDR tuberculosis developing tuberculosis disease on isoniazid preventive therapy [10, 11] . The Centers for Disease Control and Prevention identified the need for a preventive therapy trial for contacts of MDR tuberculosis in 1992 [12] . Since then, numerous international agencies and experts have also recommended that the investigation of MDR tuberculosis preventive therapy should be a global public health priority [1, [13] [14] [15] . However, no trials have been conducted to date.
One of the major concerns regarding the provision of preventive therapy in children using drugs other than isoniazid is potential toxicity in healthy children. In the treatment of MDR tuberculosis disease, the risk-benefit ratio of potentially toxic therapy is relatively clear. In contrast, this risk-benefit ratio is altered when using potentially toxic preventive therapy in children who are currently well but at risk of developing future disease. Particular caution has been exercised regarding the use of the fluoroquinolones in children, based on early animal model data showing damaging effects to the cartilage growth of young beagles [16] . There are limited published data regarding the efficacy, tolerability, and toxicity of preventive therapy regimens given to children exposed to MDR tuberculosis.
The World Health Organization (WHO) estimates that there were 650 000 prevalent cases of MDR tuberculosis in 2010 [17] . A previous MDR tuberculosis contact study suggested that in a setting with a high burden of tuberculosis, there are nearly 2 child contacts for each adult tuberculosis source patient [18] . As many as a million children could therefore be exposed to MDR tuberculosis globally each year, many of whom, in the absence of effective preventive therapy, will go on to develop MDR tuberculosis disease. While treatment outcomes for MDR tuberculosis disease are good with tailored individualized therapy in children, the treatment in children is complex, long, and associated with significant adverse events [19] . Appropriate drugs and child-friendly formulations are limited, and interactions between antiretroviral and anti-tuberculosis drugs are common [20, 21] . MDR tuberculosis is expensive to treat and often requires prolonged hospitalization [22] . We therefore aimed to study the tolerability and toxicity of a standard MDR tuberculosis preventive therapy regimen given to children following documented exposure to adults with MDR tuberculosis, and determine how many children develop poor outcomes.
METHODS

Setting
The Western Cape province of South Africa had a tuberculosis notification rate of 976 per 100 000 in 2009 [23] . Among children with culture-confirmed tuberculosis at the regional referral hospital for pediatric drug-resistant tuberculosis, Tygerberg Children's Hospital (TCH), 8.9% had MDR tuberculosis during 2007-2009 [24] . Children exposed to a person with an infectious case of MDR tuberculosis are routinely referred to a specialist pediatric drug-resistant tuberculosis clinic at TCH, or to community outreach clinics served by a specialist from this hospital.
Standard of Care
Following exclusion of tuberculosis disease through history, clinical examination, and plain film chest radiology (with mycobacterial culture in the presence of symptoms or abnormal chest radiography), children who were <5 years of age or HIVpositive, with significant exposure to an infectious (sputum smear or culture positive) pulmonary MDR tuberculosis source patient, were routinely given a regimen of MDR tuberculosis preventive therapy, irrespective of tuberculin skin test (TST) result, as advised by provincial guidelines. Significant exposure was defined as living with or having regular daily interaction with the MDR tuberculosis source patient. If the source patient had MDR tuberculosis with susceptibility to the fluoroquinolones, the child was given ofloxacin (15-20 mg/kg daily; the only fluoroquinolone available for children at the time), ethambutol (20-25 mg/kg daily), and isoniazid (15-20 mg/kg daily) for 6 months. Children were routinely evaluated at 2, 4, 6, and 12 months, at TCH or the community outreach sites, through clinical evaluation and chest radiography. Drugs were dispensed at local community tuberculosis clinics, on either a daily, weekly, or monthly basis, depending on clinic and patient preference. HIV testing was offered to all child tuberculosis contacts following informed consent from the parent or legal guardian, with assent from the child where appropriate. An enzyme-linked immunosorbent assay was used in children aged >18 months or DNA polymerase chain reaction if younger or breast-fed. Combination antiretroviral therapy was routinely initiated in all HIV-positive children following appropriate evaluation. TST was completed by tuberculosis clinic personnel by injecting 2 tuberculin units intradermally ( purified protein derivative RT23, Statens Serum Institut) with results read at 48-72 hours; an induration of ≥10 mm (or ≥5 mm if HIV positive) was regarded as positive.
Study Population and Eligibility
All children evaluated at TCH or community outreach clinics were eligible if they had been in significant contact with an individual with an infectious case of pulmonary MDR tuberculosis ("source patient") within the preceding 6 months and if the drug susceptibility test of the isolate from the source patient showed susceptibility to ofloxacin. Children were enrolled if they had started preventive therapy from May 2010 through April 2011. Children were recruited following written, informed consent from their caregivers with assent from the child where appropriate. The study was approved by the Stellenbosch University and London School of Hygiene and Tropical Medicine ethics committees.
Data Collection
Children were seen by the study team at their routine clinical appointments, as well as at any additional, unscheduled visits. At the initial interview, following screening for tuberculosis disease, data were collected regarding demographic and clinical details. At follow-up visits, after clinical assessment, parents/ caregivers were interviewed concerning adherence and potential drug-related adverse events using a structured questionnaire. In addition, during the first half of 2012, children were traced and either recalled to the clinic or visited at their local clinic or home by the study team. Where this was not possible, local clinics and families were contacted to confirm that the child was clinically well and was gaining weight. The date of this final interaction was recorded. Follow-up time for the children, therefore, was a minimum of 12 months and up to 24 months in some children. Adherence was measured in 2 ways at each study visit. The first was a 3-day recall and the second a 30-day visual analogue score. Each of these 2 measures was scaled to give a score out of 30. Scores derived from both measures from each visit were added to determine a total "score" for the whole period on treatment [25, 26] . If this was >80% of a possible maximum then adherence was recorded as good, with scores <80% as poor [27] . Local clinics were also contacted to verify medication uptake. In cases of discrepancy, adherence was reported as being poor. Adverse events to medications were categorized using the National Institute of Allergy and Infectious Diseases' Division of Microbiology and Infectious Diseases (DMID) system [28] . (Table 1 ). As arthralgia is not categorized in this classification, we allocated 5 grades consistent with the DMID classification. If old enough to cooperate, visual toxicity was evaluated with Ishihara charts. Parental impression of visual function was used for children who could not be evaluated in this way. Study outcomes were as follows: well at the end of the observation period, death of any cause, and incident tuberculosis disease. Standardized research definitions were applied to classify incident tuberculosis disease in children [29] ; confirmed and probable disease were considered incident tuberculosis. Where patients were lost to follow-up, their censoring date was recorded as the last interaction with the study team. A combined endpoint of incident tuberculosis and/or death was classified as poor outcome.
Data Analysis
Data were double-entered and checked for entry errors. Data were analyzed using Stata software, version 11 (StataCorp, College Station, Texas). Cohort analysis was undertaken to examine factors associated with poor outcome. Time of entry into the cohort was the date of recruitment and time exiting the cohort was the date of death, diagnosis of incident tuberculosis, or date of last contact with the study team. Due to the small number of events, exact Poisson analysis was undertaken for a limited number of predetermined characteristics of the child and treatment, with rate ratios (RRs), 95% confidence intervals (CIs), and P values calculated.
RESULTS
Of 245 children initially eligible, 186 were included as contacts of 164 MDR tuberculosis source patients. Of the children excluded, 12 were brought by an adult who could not provide legal consent; for 2 children consent was not given; 29 were contacts of MDR tuberculosis source patients with additional resistance to ofloxacin; and in the remainder (n = 16), although the source patient was said to have MDR tuberculosis at the initial assessment, and the child was initially given MDR tuberculosis preventive therapy, the adult was subsequently confirmed to have resistance to only either isoniazid or rifampin. For the children included, the median age was 34 months (interquartile range [IQR], 14-47), and 102 (55%) were boys ( Table 2 ). The mean weight-for-age z score was 0.59 standard deviations below the reference population. Of 179 children tested for HIV, 9 (5.0%) were positive. Adherence was good in 141 (75.8%) children, and only 2 children were lost to followup before 12 months.
Adverse events are demonstrated in Table 3 , with all grade 3 adverse events shown in Table 4 . Of the 6 children (3.2%) who experienced a grade 3 adverse event, 3 were associated with inadvertent overdosing of ofloxacin. No adverse events necessitated the discontinuation of preventive therapy, and all resolved without intervention. The most common grade 2 or higher adverse events were loss of appetite and nausea (12 children [6.2%]), itchy skin (9 children [4.7%]), disturbance of sleep or mood (7 children [3.6%]), and skin rash (7 children [3.6%]).
Over a total of 219 patient-years of observation time, 1 child died (0.5%; most likely of sudden infant death syndrome) and 6 developed incident tuberculosis (3.2%). All had probable disease ( Table 5 ). The rate for poor outcome was 31.9 outcomes (95% CI, 12.8-65.9) per 1000 patient years of follow-up. Factors associated with increased risk of poor patient outcome ( 
DISCUSSION
We demonstrate that the provision of MDR tuberculosis preventive therapy in child MDR contacts is well tolerated, associated with few clinically significant adverse events, and results in a low rate of incident tuberculosis or death. The 3 cases of grade 3 toxicity, associated with inadvertent overdosing of ofloxacin, is concerning. In South Africa, at the time our study was conducted, ofloxacin was available in 2 formulations: 200 mg and 400 mg. Medications are frequently dispensed as loose tablets within a resealable packet with the number of tablets to be taken written on the outside. If the packet is refilled with a different strength of tablet, confusion can occur. We noted only one grade 2 or higher episode of joint, muscle, or bone pain. Given the historical concerns regarding fluoroquinolone use in children, these findings are reassuring. We also observed no hepatotoxicity or visual problems. During >200 patient-years of follow-up, only 1 child died and 6 developed incident tuberculosis. It is likely that the child who died did not develop tuberculosis but died of some other illness. Of the 6 children who developed incident tuberculosis, 4 were not given the prescribed medications conscientiously, and no children given medications under daily observed therapy developed tuberculosis. Risk factors for poor outcome included young age (<12 months) and HIV infection. These risk factors are well described in the drug-susceptible pediatric tuberculosis literature [2, 3] and should prompt enhanced vigilance in these especially vulnerable populations. That children At the 2-mo appointment, the mother reported the child to be having hallucinations and sleep problems. Child had been prescribed 300 mg ofloxacin but inadvertently given 600 mg by clinic staff. Symptoms resolved on correct dosage 45 mo M Negative Insomnia At the 2-mo appointment, the mother reported that the child did not sleep at all. Child had been prescribed 300 mg ofloxacin but inadvertently given 600 mg by clinic staff. Symptoms resolved on correct dosage
Abbreviations: F, female; HIV, human immunodeficiency virus; M, male.
exposed to multiple source cases had higher rates of poor outcome is interesting. It may be that having multiple source cases increases the risk of mycobacterial transmission or it may be that highly virulent strains circulate in some households. It may be that genetic factors render certain families more susceptible to tuberculosis or it may be that social factors such as crowding, alcohol, drugs, nutrition, or adherence influence both the adults and the children. Few studies have previously assessed preventive therapy for child contacts of MDR tuberculosis, and no randomized controlled trials have been conducted [30] . One study in Cape Town examined 105 children; 41 were given a multidrug preventive regimen tailored to the drug susceptibility test pattern of the source case isolate [18] . Only 2 of the 41 treated patients (5%) developed tuberculosis disease compared to 13 (20%) observed without treatment. A study in Rio de Janeiro followed 218 adult and child contacts of MDR tuberculosis; 45 had been given isoniazid [31] . There was no protective effect of the isoniazid. A final study in Chuuk, Federated States of Micronesia, examined 110 infected adult and child MDR tuberculosis contacts given a 12-month individually tailored multidrug preventive regimen under directly observed therapy. No patients given preventive therapy developed tuberculosis [32] . Guidelines vary [33] [34] [35] , as do expert opinion [36, 37] and published practice [11, [38] [39] [40] [41] . Some agencies advise careful follow-up alone [7, 42] , some recommend isoniazid [43] , some suggest 2 drugs to which the index patient's tuberculosis strain is susceptible [12] , and some advocate specialist referral [44] . A Delphi survey of experts was unable to reach consensus [45] , and 2 systematic reviews concluded that there was not enough evidence to inform policy development regarding MDR tuberculosis preventive treatment [46] . A report from the European Centre for Disease Prevention and Control suggest that either tailored preventive therapy with close follow-up or close follow-up alone are acceptable options in the absence of better data [13] . This is the largest study to date documenting the effect of a standard preventive therapy regimen for children exposed to MDR tuberculosis. Follow-up was good, and both adherence and adverse events were carefully documented. However, our study had several limitations. Because this was an observational study without a control group, it is not possible to conclude with certainty that this regimen is effective. It is possible that the number of children developing tuberculosis could have been similar had they been given isoniazid alone or even no medications at all. However, the prechemotherapy data do not support this argument. In the absence of preventive therapy, it has been shown that up to 50% of M. tuberculosis-infected children <12 months of age developed tuberculosis disease [2] . The figure is 20%-30% for children aged between 1 and 2 years and 5% for children aged between 2 and 5 years. Although only 40% of our cohort was TST positive, we would still expect to see far higher numbers of children developing tuberculosis if the regimen was not effective. In addition, the evidence that poor adherence to preventive therapy was strongly associated with poor outcome adds support to the argument that this regimen is effective in reducing the risk of progression from infection to disease. We included children irrespective of TST status, consistent with national and provincial guidelines. The rationale for this is that TST is not a highly sensitive test for M. tuberculosis infection, especially in the young infant, HIV-positive children, and malnourished children; nor is it highly specific in settings where BCG is routinely given at birth such as ours. By only including TST-positive children, a number of infected children would therefore have been excluded. Also, if a TST is negative at the time of initial assessment, there is a chance that the child may have been infected but may only convert their test later. Rather than use a 2-stage protocol with all children started on preventive therapy, which is then stopped if a second TST at follow-up is negative, the local policy is for all exposed children to be treated. We employed these operational entry criteria in our study. It could, therefore, be argued that some of the children in the study did not require treatment. As mycobacteria were not isolated from any of the children who developed tuberculosis, we were unable to determine if this preventive therapy regimen resulted in increased rates of fluoroquinolone resistance. This is a potential concern and should be evaluated in future studies. A final limitation of the study is the duration of follow-up. All children were followed for a minimum of 12 months with some followed for 24 months. Although the vast majority (>90%) of children who develop disease do so within 12 months of infection [4, 18] , it is accepted that some children might progress to disease after the period of observation.
To conclusively determine the utility of preventive therapy for child contacts of MDR tuberculosis, a clinical trial is warranted, one in which children are randomly and blindly assigned to either a fluoroquinolone-containing multidrug regimen or to isoniazid alone. However, until that time, clinicians will continue to be confronted by children exposed to MDR tuberculosis. We have demonstrated this regimen to be well tolerated and associated with limited toxicity. Also, clinicians should be confident when managing a child exposed to MDR tuberculosis that providing this preventive therapy regimen results in reassuringly low rates of tuberculosis or death. running of the study (Helen Opperman, Elizabeth J. Perez, Sarah S. Faro, Rachel A. Solomon, Mary Petersen, Rina Plaatjies, Nadia J. Lackay, Sharen Daniels, and Nertisha Newman). Financial support. This work was supported by a US Agency for International Development Cooperative Agreement (TREAT TB, Agreement No. GHN-A-00-08-00004-00 to J. A. S. and H. S. S.), the Sir Halley Stewart Trust (to J. A. S.), and the National Research Foundation of South Africa (to H. S. S.).
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